Ubiselect Kit Utility

The Ubiselect Kit is designed to facilitate the isolation and identification of your ubiquitylated proteins of interest from a transgenic mouse-derived embryonic fibroblast (MEF) cell line expressing ubiquitin tagged with an N-terminal biotinylation signal (which is biotinylated by co-expression of the BirA enzyme). By employing a powerful capture system which utilises the transgenic MEF cell line expressing ubiquitin – which is biotinylated in the cell – and the high affinity biotin-avidin interaction alongside a high stringency washing protocol you can capture your ubiquitylated target of interest without any associated ubiquitin binding proteins and/or ubiquitylated protein binding proteins. The Ubiselect Kit contains an aliquot of each of the control Ubiselect-MEF_BirA (P0) and the Ubiselect-MEF_Bio-Ub (P0) cell lines and an anti-ubiquitin conjugate antibody for the detection of ubiquitylated proteins. Eluted captured products may be analysed by Western blotting using the ubiquitin conjugate specific antibody, an anti-biotin antibody or an antibody specific to your protein of interest.

Ubiquigent Limited is a specialist developer and supplier of Drug Discovery Services, high quality Research Tools and Chemistry to the life science research community worldwide.

Ubiquigent’s scientific and business interests have a clear focus; namely the ubiquitin, ubiquitin-like, and integrated signalling systems.

The Company has established its scientific and business credentials with both academic researchers undertaking fundamental scientific discovery and pharmaceutical and biotechnology company scientists exploring the potential of ubiquitin cascade-focused drug discovery.

Ubiquigent benefits from high calibre backing including from private US investors, the UK Medical Research Council, and the University of Dundee. The Company’s headquarters and laboratory operations are based in the UK and are located in a state-of-the-art facility adjacent to the MRC Protein Phosphorylation and Ubiquitylation Unit at the University of Dundee (both founded by Professor Sir Philip Cohen). In addition to Ubiquigent’s own facilities and capabilities, such proximity provides ready access to a huge range of additional scientific expertise (1,000+ life-science researchers on site), technological competencies, and assay and analytical platforms.

Ubiquigent staff have a wealth of scientific experience, technological competencies and commercial expertise, gained from within academia, the life science research reagents and services sector, and the pharmaceutical industry, that enables the Company to offer a level of understanding and service to its customers and clients worldwide that few companies may match.